FDA's Radiopharmaceutical Drugs Advisory Committee
Executive Summary
Will review NDAs for two myocardial imaging agents, Squibb's Cardiotec (technetium Tc99m teboroxime) and DuPont's Cardiolite (technetium Tc99m sestamibi), at its scheduled Nov. 17 meeting in Conference Rooms G and H of FDA's Parklawn Building.